NEW YORK (GenomeWeb News) – Swiss firm Lonza said today that it has acquired cell research products firm amaxa for an undisclosed sum.
Lonza expects the acquisition to strengthen the cell discovery business of its Lonza Bioscience division, which supplies primary cells and serves a similar customer base to that of amaxa. Cologne, Germany-based amaxa’s Nucleofection technology is used to transfer DNA or RNA into cells that are considered difficult to transfect.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.